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Abstract
Background: To compare the lifetime costs of liberating patients from spectacles after cataract
surgery by implanting the multifocal intraocular lens (IOL) 'ReSTOR®' versus monofocal IOLs in
France, Italy, Germany and Spain.
Methods: A Markov model was created to follow patient cohorts from cataract surgery until
death. Prevalence rates of patients not needing spectacles after cataract surgery were obtained
from clinical trials. Resource utilisation included implant surgery, IOLs, spectacles, visits to
ophthalmologists and eye centres, transport, and time lost by patients. Economic perspectives
were those of Society and Sickness Funds (SFs).
Results: The mean number of spectacles purchased after ReSTOR® was 1.34–1.61 and after
monofocal IOLs 6.05–7.27. From the societal perspective, total cost estimates discounted by 3%
were between €3,551 and €4,052 with ReSTOR® compared to €3,989 and €5,548 with monofocal
IOLs. Undiscounted savings related to ReSTOR® ranged from €815 to €2,164. From the SFs'
perspective total cost estimates discounted by 3% were between €2,150 and €2,524 with
ReSTOR® compared to €2,324 and €2,610 with monofocal IOLs. Savings related to ReSTOR®,
once costs discounted, ranged from €61 to €219. Discount and spectacle freedom prevalence
rates were the most sensitive parameters.
Conclusion: The bulk of the savings related to ReSTOR® were realized outside the SF. From both
a societal and SF perspective, savings, after a 3% discounting, achieved by liberating patients from
spectacles counterbalanced the initially higher cost of ReSTOR®. ReSTOR® is a cost saving
alternative to spectacles for patients requiring cataract surgery.
Background
Typical senile cataract progresses slowly and can cause
vision loss if untreated. An estimated 20.5 million
(17.2%) Americans older than 40 years have a cataract in
at least one eye [1].
While cataract is the leading cause of blindness in the
world [2,3] most developed Western populations have
access to cataract surgery (e.g., 6.1 million American citi-
zens (5.1%) have pseudo-phakia/aphakia). The total
number of Americans with cataract is predicted to increase
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to 30.1 million by 2020 and of these 9.5 million are
expected to have pseudo- phakia/aphakia [1].
More than 80% of patients regain good best-corrected vis-
ual acuity (≥ 8/10) after cataract surgery, depending on
other ocular pathology and the duration of follow-up [4-
8].
Traditional intraocular lenses are monofocal and after
implantation most patients need spectacles for at least
near vision. Multifocal IOLs are meant to free patients
from spectacles after presbyopia or cataract surgery by
applying the principle of simultaneous vision [9].
Improvements in intraocular lens technology have per-
mitted cataract patients to be implanted with multifocal
IOLs providing better visual acuity at various distances
and a degree of spectacle independence [10]. Early MIOLs
were initially associated with loss of clarity and accommo-
dation, reduced contrast sensitivity, and complaints of
halos and glare. Today, MIOLs produce functional near
and distance vision in everyday practice and an acceptable
level of patient satisfaction [11-25]. Recently, a new apo-
dised IOL (ReSTOR®) was marketed that combines effi-
cacy at both near and distant vision (80% of the patients
never wear spectacles).
According to Vitale et al. [26] more than 110 million
Americans either could, or do, achieve normal vision after
refractive correction. However, spectacle prescriptions
incur costs for both patients and health insurance provid-
ers. The annual direct cost of simply correcting impaired
distance vision was at least $3.8 billion of which $780
million concerned persons aged > 65 years. To our knowl-
edge no data have been published on the costs associated
with wearing spectacles after cataract surgery apart from a
survey conducted by Cuq et al. [27] in France, Germany,
Italy and Spain, which found costs varying from €230
(Spain) to €579 (France). Cost savings have been esti-
mated for 'laser-assisted in situ keratomileusis' (LASIK)
[28], but to date no lifelong data have been published for
multifocal IOLs.
The aim of this economic analysis was to compare the life-
time costs and consequences of liberating patients from
spectacles by implanting the multifocal IOL 'ReSTOR®'
versus monofocal IOLs after cataract surgery.
Methods
This economic study used a Markov model to estimate the
lifetime cost consequences for Society and Sick Funds
(SFs) in four European countries (France, Germany, Italy
and Spain) after implanting monofocal IOLs, multifocal
IOLs or ReSTOR® bilaterally during cataract surgery. Tree-
Age software version 4.0 was used to build a Markov
model simulating cohorts of patients implanted with
identical IOLs into both eyes during cataract surgery at age
70 years, followed until death or age 100 years.
Four Markov states were created (Figure 1) as follows: "No
needs of glasses", "Buy glasses", No glasses purchase" and
"Death", the absorbing state. Thus, after cataract surgery
patients presented with one of two possible health states,
either "No needs of glasses" or "Buy glasses". The fre-
quency rate of "No needs of glasses" was derived from
controlled clinical trials. Patients starting in the "Buy
glasses" state were included and remained in the "No
glasses purchase" until they bought spectacles, after which
they joined the "Buy glasses" state for one cycle.
The duration of a cycle was 1 month and patients were
eliminated at death or on reaching 100 years of age.
National mortality statistics were used for life expectancy
[29-32].
The following assumptions were made when constructing
the model:
￿ A patient freed from spectacles by an MIOL would
remain spectacle free for life (MIOLs are implanted for
decades of use)
￿ The spectacle type prescribed after a monofocal IOL
implant was assumed, conservatively, to be similar to that
after an MIOL (whereas monofocal spectacles are more
frequently provided after MIOLs)
￿ Outside the near vision benefit, the risk-benefit ratio
with MIOL surgery was made similar to that for monofo-
cal IOLs
￿ Patients given excimer laser surgery following MIOL
implantation were excluded, as stipulated in the protocol
that established the ReSTOR® spectacle independence rate
￿ Age was associated with death only, and not with the
cost of spectacles.
The base-case analysis compared two groups of patients,
patients implanted with ReSTOR®  in both eyes versus
patients with monofocal IOLs in both eyes.
A three-way sensitivity analysis was performed on the pri-
mary sensitive parameters, i.e. discount rates (0%, 3% and
5%), multifocal IOL premiums (€0, €250 and €500) and
prevalence of spectacle independence (20%, 40%, 60%
and 80%).
Efficacy and resource utilisation
In a study submitted to the FDA [33], ReSTOR® achieved
80% rates of spectacle independence for both distanceBMC Ophthalmology 2008, 8:12 http://www.biomedcentral.com/1471-2415/8/12
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and near vision, figures much higher than reported previ-
ously for other multifocal implants. ReSTOR® also pro-
vided qualitatively better visual acuity and spectacle
independence, with tolerable unwanted photic phenom-
ena [22,23,34] from both the clinical and patients' per-
spectives. In the base-case analysis, spectacle freedom
prevalence rates were fixed at 80% for ReSTOR® and 10%
for monofocal implants.
A survey was carried out across four countries to estimate
the costs of wearing spectacles after cataract surgery. The
patient sample [27] was recruited by ophthalmologists
and given a questionnaire to answer. Resources consumed
and the associated costs of cataract surgery were itemised,
as follows: (1) surgical operation (both eyes); (2) two
implants (monofocal or ReSTOR®); (3) time spent on sur-
gery (including transport); and (4) other transport to the
Model schema Figure 1
Model schema.BMC Ophthalmology 2008, 8:12 http://www.biomedcentral.com/1471-2415/8/12
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clinic. Resources consumed by a patient needing specta-
cles were, as follows: (1) consultation with ophthalmolo-
gists or optometrists for prescriptions; (2) transport and
time spent during the visit; (3) visits to the optic centres;
(4) time spent in choosing and collecting spectacles; and
(5) transport to the ophthalmologist's or optometrist's
office. An annual rate for spectacle replacement was esti-
mated from the survey.
In addition to the model, the following resources were
consumed periodically by patients wearing spectacles: (1)
visits to an optic centre for frame maintenance; (2) time
spent on the visit; (3) cleaning devices purchased; and (4)
transport to the optic centre.
Costing
Results are expressed as 2006 euros. A discount rate of 3%
was fixed for the base-case analysis.
National tariffs and estimates were used to cost medical
resources consumed (Table 1). The following unit costs
were estimated from national tariffs and available sources:
(a) according to a European survey [27] most people
spend from €200 to €400 for a pair of spectacles, except
in France where the majority pays more than €500. Spec-
tacle costs were not reimbursed, except in France [35]. In
France, national health service (NHS) tariffs vary accord-
ing to age (above or below 18 years) and the degree of
optical correction. For subjects above 18 years lenses are
reimbursed at 65% and frames are reimbursed at 65% of
a fixed tariff of €2.84;
(b) the average cost of cataract surgery varied from €1,050
in Spain to €1,250 in Germany, including the cost of a
monofocal intraocular implant [36-39];
(c) for the societal perspective, an estimated €500 was
added to the cost of cataract surgery with ReSTOR®, as a
premium for spectacle independence; in the absence of
published data, this figure was estimated from our knowl-
edge of the market.
(d) ophthalmologists' consultation fees varied from €25
in France to €100 in Italy, with optometrists' costs influ-
enced by official regulations, i.e. in Italy and Germany
optometry is not a recognised profession and many
optometrists do not charge for a visit, whereas in Spain
optometrists' costs are regulated at €40 without NHS
reimbursements [37,40-43];
(e) spectacle cleaning materials vary widely in cost,
according to package size, brand and type of accessories
(spray, cloths and chains), hence an approximated aver-
age cost of €3 was applied to the present analysis;
(f) as costs per kilometre and type of transportation dif-
fered between countries (taxis from €0.9 in France to
€1.80 in Spain, with subway and bus costs similar at
about €0.20-€0.30, depending on the ticket and distance
covered) different internet sources [44-47] were solicited
to obtain an approximated average cost of €0.40 per kilo-
metre weighted by the proportion of subjects using the
various types of transportation [27]; distances to ophthal-
mologists varied from 11.9 to 29.1 km, and distances to
optic centres from 6.5 to 13.4 km [27].
Table 1: Unit costs according to country and type of resource consumed (2006 €)
Item France Germany Italy Spain
Society NHS Society NHS Society NHS Society NHS
Cataract surge'ry
• Surgery [35-38] 1,145.9 1,145.9 1,250 1,250 1,106 1,106 1,050 1,050
• ReSTOR® premium1 5 0 00 5 0 00 5 0 00 5 0 00
• Monofocal IOLs In DRG In DRG In DRG In DRG In DRG In DRG In DRG In DRG
• Other multifocal IOLs2 [ 0 – 5 0 0 ]0 [ 0 – 5 0 0 ]0 [ 0 – 5 0 0 ]0 [ 0 – 5 0 0 ]0
Spectacles [25,34] 578.9 19.71 387.6 0 310.5 0 230.2 0
Unit cost of cleaning 3 3 3 3
Visit [39-42]
• ophthalmologist 25 16.50 57.78 23.75 100 12.91 60 60
• optometrist - - 0 0 0 0 40 0
Mean cost per km [43-46]
• visit/implant 0.39 - 0.27 - 0.31 - 0.46 -
• optic centre 0.31 - 0.23 - 0.31 - 0.45 -
Cost of work/hour [47] 24.7 - 26.22 - 21.39 - 14.75 -
1 Fixed arbitrarily at €500
2 Analysed by sensitivity analysisBMC Ophthalmology 2008, 8:12 http://www.biomedcentral.com/1471-2415/8/12
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(g) time spent was economically valued using estimated
hourly earnings published by the European Union Statis-
tical Office [48].
Results
According to the Markov model and using national mor-
tality statistics for each country, the average life expect-
ancy of patients aged 70 years in the four European
countries ranged from 13.8 to 15.0 years, reflecting differ-
ences in general life expectancy from 78.4 years in Ger-
many to 80.5 years in Spain [49]. The average estimated
duration of spectacle wear with monofocal IOLs was 12.4
to 13.5 years, which was more than 4× the duration fol-
lowing ReSTOR® implants (2.8 to 3.0 years depending on
the country).
Table 2 shows average resource consumption per patient
according to the type of IOL implanted and the country.
Consistent with the average duration of spectacle depend-
ence patients implanted with monofocal lenses con-
sumed 4× more on spectacles, visits to ophthalmologists,
transportation and cleaning devices, and devoted about
three additional full weeks of life to dealing with their vis-
ual acuity compared to ReSTOR® patients.
Table 3 compares the estimated societal costs of a patient
implanted with monofocal IOLs or ReSTOR® according to
our base-case scenario. In all countries, the incremental
cost of ReSTOR® was less than the savings achieved with
spectacle independence. Major savings related directly to
the cost of spectacles, followed by time spent and trans-
portation. Lastly, ReSTOR® enabled cost savings even in
the country where spectacles cost the least (Spain,
€230.2). Lifelong 3% discounted savings ranged from
€547 to €1,741.
Table 4 presents the estimated NHS costs of a patient with
a monofocal IOL, as compared to a ReSTOR® implant,
according to our base-case scenario. In contrast to Table 3,
it would appear that the NHS is not a major stakeholder
as its costs represented less than one-half the costs of soci-
ety. Nonetheless, savings were realised by all countries
which did not reimburse visits for visual acuity control.
These savings ranged from 3.1 to 26.5× times less than
those realised by society.
Tables 5 and 6 describe three-way sensitivity analyses for
each economic perspective. After multifocal IOLs it was
necessary for the prevalence rate of freedom from specta-
cles in France to reach about 20% before they became less
expensive than monofocal IOLs, There was a 40% rate in
Germany and Italy. In Spain, the country with the lowest
cost of spectacles, a freedom from spectacle rate of almost
80% was needed in the most extreme situation (i.e. dis-
count rate 5% and €500 premium). From a NHS perspec-
tive savings ranged between €6 and €170.
Discussion
This economic analysis estimated cost consequences until
death or age 100 years, of cataract surgery performed at
age 70, using ReSTOR® or monofocal implants, in four
European countries (France, Germany, Italy and Spain).
The economic perspectives were those of society and Sick
Funds. Whereas ReSTOR® is a new technology approved
for cataract patients, monofocal IOLs today remain wide-
spread as the standard of care during cataract surgery.
Except in France, where reimbursement rates are low,
spectacles were not covered by national health services
although these countries financed almost 100% of cata-
ract surgery and visits to ophthalmologists for vision cor-
rection. Irrespective of the type of implant used, cataract
Table 2: Average resources consumed in the Markov model period according to ReSTOR®, monofocal implants and countries
Item France Germany Italy Spain
ReSTOR® Monofocal ReSTOR® Monofocal ReSTOR® Monofocal ReSTOR® Monofocal
Number of spectacles 1.34 6.05 1.44 6.49 1.61 7.27 1.45 6.52
Number of units purchased to 
clean spectacles
7.5 33.9 4.55 20.46 7.02 31.59 2.97 13.34
Visit to ophthalmologist to 
correct visual acuity
1.34 6.05 1.28 5.77 1.34 6.03 0.94 4.24
Visit to optometrist to correct 
visual acuity
---- 0 . 2 7 1 . 2 4 0 . 5 2 . 3
Transportation ophthalmologist 
(km)
1 9 54 6 8 8 2 2 0 21 8 24 6 61 5 03 7 0
Transportation optic centre (km) 127 573 87 390 180 808 157 705
Time spent to care for visual 
acuity (h)
44.5 57.0 43.9 53.9 45.2 60.1 43.6 52.9
Base-case scenario: cost of ReSTOR® = €500; discount rate = 3%; patients freed from spectacles = 80% after ReSTOR® versus 10% after monofocal 
IOLs.BMC Ophthalmology 2008, 8:12 http://www.biomedcentral.com/1471-2415/8/12
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surgery reimbursement always included the price of a
standard implant (i.e. monofocal IOLs).
Our study was based on national data (mortality and
prevalence of cataract), clinical trials, and a survey in all
four countries. The concomitant use of clinical trials and
national survey data offered good guarantees of internal
and external validity, as recommended by most health
economics guidelines [50].
With a time horizon of 30 years and a 3% discount rate,
ReSTOR® implantation with 20% of patients wearing spec-
tacles after surgery was always more beneficial over mono-
focal IOLs, regardless of the country. At a incremental cost
of €500, ReSTOR® enabled savings from €547 (Spain) to
€1,741 (France), relative to monofocal IOLs. From a Sick-
ness Fund perspective, ReSTOR® was always the better
strategy since it avoided a significant number of visits to
ophthalmologists and optometrists for refraction. The fact
that the discount rate significantly modified our results is
not surprising due to the long follow-up period built into
our model (up to 30 years). Two variables drove the eco-
nomic benefit of ReSTOR®, i.e. time and spectacle inde-
pendence.
We tried to maintain a very conservative approach. The
mean number of broken spectacles was calculated for
each country from a spectacle survey [27] and we chose
the lowest mean rate.
We valorised time spent using hourly earnings even
though most of our population was retired. This was
appropriate, as patients with spectacles are obliged to
spend time caring for them and such time is lost to other
use, whether productive, for leisure or something else.
Patients may be willing to pay for spectacle care and this
should be taken into account. However, valorising wasted
time is always a normative exercise which is why we give
two total counts, i.e. with and without spectacle cleaning
time.
The 80% incidence rate of freedom from spectacles in this
model was based on a clinical trial where excimer laser
surgery (ELS) was not permitted and so not taken into
Table 3: Cost consequences (€) according to ReSTOR® and monofocal IOLs per country from the societal perspective
Item France Germany Italy Spain
ReSTOR® Monofocal ReSTOR® Monofocal ReSTOR® Monofocal ReSTOR® Monofocal
Surgery including the IOL 3,292 2,292 3,500 2,500 3,212 2,212 3,100 2,100
Spectacles 615 2,766 447 2,009 394 1,772 334 1,501
Clean spectacles 17.5 78.5 11 48 16 73 9 40
Visit to correct visual acuity 27 119 59 267 105 474 77 346
Transportation 100 292 36 117 94 314 140 487
Total without time spent 4,051 5,548 4,052 4,941 3,821 4,844 3,551 3,989
Time spent 1,081 1,324 1,134 1,344 947 1,197 635 744
Total including time spent 5,132 6,872 5,186 6,285 4,769 6,041 4,186 4,733
Difference -1,741 Ref -1,099 Ref -1,272 Ref -547 Ref
Base-case scenario: cost of ReSTOR® = €500; discount rate = 3%; patients freed from spectacles = 80% after ReSTOR® versus 10% after monofocal 
IOLs, Ref: Reference
Table 4: Cost consequences (€) according to ReSTOR® and monofocal IOLs per country according to NHS perspectives
France Germany Italy Spain
Item ReSTOR® Monofocal ReSTOR® Monofocal ReSTOR® Monofocal ReSTOR® Monofocal
Surgery including the IOL 2,292 2,292 2,500 2,500 2,212 2,212 2,100 2,100
S p e c t a c l e s 2 1 9 4 000000
Visit to correct visual acuity 17 79 24 110 14 61 50 224
Total 2,330 2,465 2,524 2,610 2,226 2,273 2,150 2,324
Difference -135 Ref -85 Ref -48 Ref -174 Ref
Base-case scenario: cost of ReSTOR® = €500; discount rate = 3%; patients freed from spectacles = 80% after RESTOR® versus 10% after monofocal 
IOLs. Ref: ReferenceBMC Ophthalmology 2008, 8:12 http://www.biomedcentral.com/1471-2415/8/12
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account. However, ELS is often performed in everyday
practice with a consequently higher incidence of freedom
from spectacles and greater savings. According to the
results in Table 5, a 10% reduction of the spectacle inci-
dence rate in France (discounting = 0%) results in a saving
of €452 (time spent excluded). A field study of the costs
and consequences of ELS following multifocal lens
implantation is needed for a closer approximation to eve-
ryday practice.
Non-financial benefits of being free of spectacles after cat-
aract surgery were not evaluated in this analysis. However,
in addition to savings with ReSTOR®, patients appeared
willing to pay for the benefit of spectacle independence.
Some ReSTOR® patients reported [51] broader vision (not
restricted by a spectacle frame), feelings of well-being,
freedom and youthfulness, and improved socialisation,
etc.
Most of the published literature on ReSTOR® reports clin-
ical outcomes at 6 months, an usually short follow-up
duration for cataract surgery clinical trials. This short
period is justified by the fact that, apart from posterior
capsular opacification [52], most adverse events following
cataract surgery arise in the first few months. ReSTOR® is
made from an hydrophobic substance that the Cochrane
library has found to be associated with a lower PCO inci-
dence rate than hydrophilic materials [53]. Consequently,
the mentioned observations support the finding of Lun-
dqvist who showed that subjective and objective visual
function 5 years after cataract surgery remained stable in
most patients [54]. Lastly, the reader could use the 'spec-
tacle independence rate' variable of our 3-way sensitivity
analysis to estimate what would be the long-term impact
of resuming spectacle use, should this eventuality occur.
Our analysis has the following limitations: (1) a model
cannot replace longitudinal data collection, but the feasi-
bility and economics of such a survey can be questioned;
(2) we hypothesised that the prevalence rate of spectacle
independence remains constant until the end of a
patient's life whereas the known efficacy of ReSTOR®
implants, to date, does not yet extend that many years;
medical devices vigilance and long term patient follow-up
Table 5: Cost differences between monofocal IOLs and other multifocal IOLs (€), excluding time spent, according to freedom from 
spectacle rates, discount rates and IOL prices (societal perspective)
Spectacle dependence rates Discount Rate = 0% Discount Rate = 3% Discount Rate = 5%
€0 €250 €500 €0 €250 €500 €0 €250 €500
France
% of spectacles after MIOL 20% -3,164 -2,664 -2,164 -2,497 -1,997 -1,497 -2,182 -1,682 -1,182
40% -2,260 -1,760 -1,260 -1,784 -1,284 -784 -1559 -1,059 -559
60% -1,356 -856 -356 -1,070 -570 -70 -935 -435 65
80% -452 48 548 -357 143 643 -312 188 688
Germany
% of spectacles after MIOL 20% -2,365 -1,865 -1,365 -1,888 -1,388 -888 -1,658 -1,158 -658
40% -1,689 -1,189 -689 -1,349 -849 -349 -1,184 -684 -184
60% -1,014 -514 -14 -809 -309 191 -710 -210 290
80% -338 162 662 -270 230 730 -237 263 763
Italy
% of spectacles after MIOL 20% -2,580 -2,080 -1,580 -2,023 -1,523 -1,023 -1,759 -1,259 -759
40% -1,843 -1,343 -843 -1,445 -945 -445 -1,256 -756 -256
60% -1,106 -606 -106 -867 -367 133 -754 -254 246
80% -369 131 631 -289 211 711 -251 249 749
Spain
% of spectacles after MIOL 20% -1,815 -1,315 -815 -1,438 -938 -438 -1,258 -758 -258
40% -1,296 -796 -296 -1,027 -527 -27 -898 -398 102
60% -778 -278 222 -616 -116 384 -539 -39 461
80% -259 241 741 -205 295 795 -180 320 820
Bold: monofocal IOLs less expensive than multifocal IOLs. Spectacle freedom after monofocal IOLs = 10%. BMC Ophthalmology 2008, 8:12 http://www.biomedcentral.com/1471-2415/8/12
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will help confirming this hypothesis or not (3) the exter-
nal validity of our survey on spectacle costs could be chal-
lenged, but the cost structure was coherent across
countries [27]; (4) we valued the cost savings of avoided
refraction visits after ReSTOR® fully, which may be dis-
puted as refraction could be a marginal reason for an oph-
thalmic visit. However, avoided visits were not the main
driver of ReSTOR® savings (5) the fact that some patients
need an excimer laser procedure and/or IOL exchanges
were not included in the model.
The reported results are valid at a population level. From
an individual's perspective, the cost of spectacles is likely
to be subject to some variation, for example, patients pur-
chasing low cost spectacle are not likely to save money.
This phenomenon is well identified by our survey [27],
where patients accustomed to paying for high cost specta-
cles were the most willing to spend extra to be freed from
spectacles.
Our model showed that savings with ReSTOR® achieved in
our four European countries were mainly realised by soci-
eties, i.e. by patients. This was explained by the fact that
cost shifting occurred entirely outside national health
services which paid for cataract surgery, as usual, but not
for the costs of refraction visits; whereas patients avoided
the costs related to care and refraction treatment. It is
worth noting that the costs met by patients exceeded those
of national health services. Hence, our results support the
case that patients should be allowed complete freedom to
control their own budget for refraction correction during
cataract surgery according to their economic circum-
stances, without any economic control of the national
health service, provided the procedure has been judged as
efficacious and safe. National health services that would
deny them this right may be regarded as economically
irrational and unfairly interventionist.
Conclusion
According to our data and model for cataract, bilateral
ReSTOR® (2 × €500) implants were always a cost-saving
alternative to monofocal IOL implants when viewed from
a societal perspective. Our sensitivity analysis, conducted
on the three main drivers of uncertainty, showed that any
IOL that can provide a spectacle independence prevalence
rate > 80% would always yield our average cost savings.
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